[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PTarantinoMD Avatar @PTarantinoMD Paolo Tarantino

Paolo Tarantino posts on X about pts, $fro, see the, all the the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence technology brands X%

Social topic influence pts 10%, $fro 5%, see the 5%, all the 5%, safely 5%, $8750t 5%, reaching 5%, the only X%

Top accounts mentioned or mentioned by @kennakoehler @fedrophd @breastcancerstd @dryukselurun @ccortimd @esmoopen @vitti10 @drhburstein @curijoey @myesmo @mpishvaian @pablomando @gilesgeddes @medicalwatchhq @helenadecosta1 @eva_lpr @larvol @medwatchkate @notgenentech

Top assets mentioned Frontline Ltd. (FRO)

Top Social Posts #

Top posts by engagements in the last XX hours

"No time to wrap our head around two practice-changing trials (DB-09 PATINA) that a third innovation joins the frontline setting for HER2+ mBC. HER2CLIMB-05 is positive: tucatinib added to HP maintenance improves PFS. Could it prevent/delay brain mets 🧠"
X Link @PTarantinoMD 2025-10-14T11:20Z 29.5K followers, 14.3K engagements

"How do adjuvant CDK4/6i impact the biology of breast cancer that recurs Angie DeMichele highlights our RW study led by @CCortiMD which found XX% of pts losing ER expression and having short 1L PFS if relapsing after abema. Published in @ESMO_Open #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-17T13:28Z 29.5K followers, 12.5K engagements

"Wow. All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs 30%. No benefit with low TILs. Unbelievable that we didnt get to see the TILs data from KN522 yet. Hope well see them soon. Congrats @vitti10 #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-19T08:34Z 29.5K followers, 11.2K engagements

"Could ADCs be safely administered subcutaneously - clinical data of a sc ADC (JSKN003) just presented at #SITC2024 with favorable safety - Daiichi entered in a partnership with Alteogen to develop a sc formulation of T-DXd - -"
X Link @PTarantinoMD 2024-11-11T21:54Z 29.5K followers, 11K engagements

"Here you go âš¡"
X Link @PTarantinoMD 2025-09-19T23:40Z 29.5K followers, 17K engagements

"Asian phase X trial of Sac-TMT (Trop2 ADC) vs chemo in pretreated HR+/HER2- MBC. Impressive doubling in PFS (8.3 vs XXX mo) positive OS trend. Compares favorably with data with SG despite similar ADC structure. Phase X testing ongoing in western pts. #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-18T09:12Z 29.5K followers, 4741 engagements

"The KM curve of 2025 outside of breast oncology. Neoadjuvant EV+pembro more than halved the risk of recurrence and significantly improved OS among platinum-ineligible pts with bladder cancer. The tremendous power of ADCs + IO transforming oncology. #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-18T15:35Z 29.5K followers, 5643 engagements

"Impressive results from DB-11 with improvement in pCR rate (67% vs 56%) positive EFS trend & more favorable safety with T-DXd-THP vs ddAC-THP in high risk HER2+ eBC. Benefit mostly seen in N+ patients (90% of the pts). New neoadjuvant treatment option #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-18T14:42Z 29.5K followers, 4335 engagements

"1 mg/kg of pembro saturates PD1. Could we give a lower dose and reduce financial tox In the PLANeT randomized ph X trial low dose pembro (50 mg for X Q6W doses) added to neoadjuvant ddAC-T significantly improved pCR for stage II-III TNBC (delta 13%). #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-17T12:35Z 29.5K followers, 13.9K engagements

"One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases anticipating the expansion of T-DXd to the curative setting two Trop2 ADCs reaching first-line mTNBC X novel ET-based combos adjuvant CDK4/6i improving OS. See you in Berlin #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-09T11:13Z 29.5K followers, 33K engagements

"Such a great day. Two Trop2 ADCs (SG Dato-DXd) just replaced 1L chemo for IO-ineligible mTNBC a huge unmet need. Pros and cons for the choice of each. Dato-DXd though looked safer with no G5 toxicity (vs X deaths with SG). Proactive management of ADC toxicities is key"
X Link @PTarantinoMD 2025-10-19T09:08Z 29.5K followers, 6802 engagements

"#ESMO25 will bring two new combos for the treatment of HR+/HER2- breast cancer. How would you treat a patient with HR+/HER2- MBC with visceral mets who progresses after XX months on 1L letrozole/ribociclib and is found to have an ESR1 mutation (assuming all available)"
X Link @PTarantinoMD 2025-10-20T05:43Z 29.5K followers, 9460 engagements

"A lot of heterogeneity in the management of stage II HER2+ breast cancer. The only consensus - no anthracyclines"
X Link @PTarantinoMD 2025-10-21T06:24Z 29.5K followers, 3241 engagements